Glenmark Pharmaceuticals Limited — Q3 FY25
Glenmark delivered a strong Q3 FY25 with consolidated revenue of INR 3,388 crore, up 35.1% YoY, driven by a 300% surge in India formulation sales to INR 1,064 crore, aided by ne...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY25
Monroe plant resumption by end of FY25
Management expects to reinitiate commercial production at Monroe before end of FY25, following FDA meeting.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1